The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis

Schizophrenia Bulletin

Volumn 25, Issue 2, 1999, Pages 201-222

  Keefe, Richard S E ^a   Silva, Susan G ^b   Perkins, Diana O ^b   Lieberman, Jeffrey A ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotic drugs; Neurocognitive impairment

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 3 (1,2,5,6 TETRAHYDRO 4 PYRIDYL)PYRROLO[3,2 B]PYRIDIN 5 ONE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMANTADINE; ARIPIPRAZOLE; BENZATROPINE; BIPERIDEN; CHLORPROMAZINE; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOPAMINE RECEPTOR; FLUPHENAZINE; HALOPERIDOL; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; PIZOTIFEN; QUETIAPINE; QUINPIROLE; RACLOPRIDE; RISPERIDONE; RITANSERIN; SCOPOLAMINE; SEROTONIN RECEPTOR; TRIHEXYPHENIDYL; UNINDEXED DRUG; ZIPRASIDONE; ZOTEPINE;

CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MENTAL DISEASE; META ANALYSIS; METHODOLOGY; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; RECALL; REVIEW; SCHIZOIDISM; SCHIZOPHRENIA; SPATIAL MEMORY; TASK PERFORMANCE; VERBAL MEMORY;

EID: 0033021909     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a033374     Document Type: Review

References (108)

1. Abdulla, F.A.; Calaminici, M.R.; Stephenson, J.D.; and Sinden, J.D. Chronic treatments with cholinoceptor drugs influence spatial learning in rats. Psychopharmacology (Berlin), 111:508-511, 1993.
2. Addington, J.; Addington, D.; and Maticka-Tyndale, E. Cognitive functioning and positive and negative symptoms in schizophrenia. Schizophrenia Research, 4:123-134, 1991.
3. Aigner, T.G.; Walker, D.L.; and Mishkin, M. Comparison of the effects of scopolamine administered before and after acquisition in a test of visual recognition memory in monkeys. Behavioral and Neural Biology, 55:61-67, 1991.
4. Altman, H.J., and Normile, H.J. Enhancement of the memory of a previously learned aversive habit following administration of a variety of serotonergic antagonists in mice. Psychopharmacology, 90:24-27, 1986.
5. Altman, H.J., and Normile, H.J. What is the nature of the role of the serotonergic nervous system in learning and memory: Prospects for development of an effective treatment strategy for senile dementia. Neurobiology of Aging, 9:627-638, 1988.
6. 2 Adrenergic agonists decrease distractibility in aged monkeys performing the delayed response task. Psychopharmacology, 108:159-169, 1992.
7. 2 receptor subtypes. Journal of Neuroscience, 8:4287-4298, 1988.
8. 2 receptor mechanisms contribute to age-related cognitive decline: The effects of quinpirole on memory and motor performance in monkeys. Journal of Neuroscience, 15:3429-3439, 1995.
9. 2 Adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science, 230:1273-1276, 1985.
10. 2 noradrenergic mechanisms to prefrontal cortical cognitive function. Archives of General Psychiatry, 53:448-455, 1996.
11. Baker, L.; Cheng, L.; and Amara, I. The withdrawal of benztropine mesylate in chronic schizophrenic patients. British Journal of Psychiatry, 143:584-590, 1983.
12. Barnes, J.M.; Costall, B.; Coughlan, J.; Domeney, A.M.; Gerrard, P.A.; Kelly, M.E.; Naylor, R.J.; Onaivi, E.S.; Tomkins, D.M.; and Tyers, M.B. The effects of ondansetron, a 5-HT3 receptor antagonist, on cognition in rodents and primates. Pharmacology, Biochemistry and Behavior, 35:955-962, 1990.
13. Beatty, W., and Rush, J. Spatial working memory in rats: Effects of monoaminergic antagonists. Pharmacology, Biochemistry and Behavior, 18:7-12, 1983.
14. Bilder, R.M.; Lieberman, J.A.; Kim, Y.; Alvir, J.M.; and Reiter, G. Methylphenidate and neuroleptic effects on oral word production in schizophrenia. Neuropsychiatry, Neuropsychology, and Behavioral Neurology, 5:262-271, 1992.
15. Buchanan, R.W.; Holstein, C.; and Brier, A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biological Psychiatry, 36:717-725, 1994.
16. Buhot, M.C. Serotonin receptors in cognitive behaviors. Current Opinion in Neurobiology, 7:243-254, 1997.
17. Buhot, M.C.; Patra, S.K.; and Naili, S. Spatial memory deficits following stimulation of hippocampal 5-HT1B receptors in the rat. European Journal of Pharmacology, 285:221-228, 1995.
18. Bymaster, F.P.; Calligaro, D.O.; Falcone, J.F.; Marsh, R.D.; Moore, N.A.; Tye, N.C.; Seeman, P.; and Wong, D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology, 14(2):87-96, 1996.
19. Cai, J.X., and Arnsten, A.F. Dose dependent effects of the dopamine D1 receptor agonists A77636 or SKF 81297 on spatial working memory in aged monkeys. Journal of Pharmacology and Experimental Therapeutics, 283:183-189, 1997.
20. 2 adrenergic agonist clonidine. Brain Research, 14:191-196, 1993.
21. Calev, A. Anti-cholinergic drugs and memory. British Journal of Psychiatry, 143:422-423, 1983.
22. Carli, M.; Luschi, R.; and Samanin R. (S)-WAY 100135, a 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine. European Journal of Pharmacology, 283(1-3): 133-139, 1995.
23. Carlson, S.; Tanila, H.; Rama, P.; Mecke, E.; and Pertovaara, A. Effects of medetomidine, an alpha2 adrenoceptor agonist and atipamezole, an alpha2 antagonist on spatial memory performance in adult and aged rats. Behavioral and Neural Biology, 58:113-119, 1992.
24. Cassel, J.C., and Jeltsch, H. Serotonergic modulation of cholinergic function in the central nervous system: Cognitive implications. Neuroscience, 69:1-41, 1995.
25. Cassens, G.; Inglis, A.K.; Appelbaum, P.S.; and Gutheil, T.G. Neuroleptics: Effects on neuropsychological function in chronic schizophrenic patients. Schizophrenia Bulletin, 16:477-500, 1990.
26. Cohen, J. Statistical Power Analysis for the Behavioral Sciences. Rev. ed. Orlando, FL: Academic Press, 1977.
27. Committee for Proprietary Medicinal Products. European Public Assessment Report: Zyprexa (olanzapine). Document CPMP/646/96. London, UK: EMEA, 1996. (http:// www.eudra.org/emea/pdfs/CPMP_EPAR_646_96.pdf)
28. Conley, R.R.; Carpenter, W.T., Jr.; and Tamminga, C.A. Time to clozapine response in a standardized trial. American Journal of Psychiatry, 154:1243-1247, 1997.
29. Cooper, J.R.; Bloom, F.E.; and Roth, R.H. The Biochemical Basis of Neuropharmacology. 7th ed. New York, NY: Oxford University Press, 1996.
30. Coull, J.T. Pharmacological manipulations of the alpha 2-noradrenergic system: Effects on cognition. Drug Aging, 5(2):116-126, 1994.
31. Coull, J.T.; Middleton, H.C.; Robbins, T.W.; and Sahakian, B.J. Contrasting effects of clonidine and diazepam on tests of working memory and planning. Psychopharmacohgy, 120:311-321, 1995.
32. Davidson, M.; Harvey, P.D.; Powchik, P.; Parrella, M.; White, L.; Knobler, H.Y.; Losonczy, M.F.; Keefe, R.S.; Katz, S.; and Frecska, E. Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. American Journal of Psychiatry, 152:197-207, 1995.
33. Decker, M.W., and McGaugh, J.L. The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse, 7:151-168, 1991.
34. Earle-Boyer, E.A.; Serper, M.R.; Davidson, M.; and Harvey, P.D. Auditory and visual continuous performance tests in medicated and unmedicated schizophrenic patients: Clinical and motoric correlates. Psychiatry Research, 3:127-129, 1990.
35. Earle-Boyer, E.A.; Serper, M.R.; Davidson, M.; and Harvey, P.D. Auditory and visual continuous performance tests in medicated and unmedicated schizophrenic patients: Clinical and motoric correlates. Psychiatry Research, 37:47-56, 1991.
36. Fayen, M.; Goldman, M.B.; Moulthrop, M.A.; and Luchins, D.J. Differential memory function with dopaminergic versus anticholinergic treatment of drug induced extrapyramidal symptoms. American Journal of Psychiatry, 145:483-486, 1988.
37. Fields, R.B.; Van Kammen, D.P.; Peters, J.L.; Rosen, J.; van Kammen, W.B.; Nugent, A.; Stipetic, S.; and Linnoila, M. Clonidine improves memory function in schizophrenia independently from change in psychosis. Schizophrenia Research, 1:417-423, 1988.
38. Fletcher, A.; Forster, E.A.; Bill, D.J.; Brown, G.; Cliffe, I.A.; Hartley, I.E.; Jones, D.E.; McLenachan, A.; Stanhope, K.J.; Critchley, D.J.; Childs, K.J.; Middlefell, V.C.; Lanfumey, L.; Corradetti, R.; Laporte, A.M.; Gozlan, H.; Hamon, M.; and Dourish, C.T. Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist. Behavioural Brain Research, 73(1-2):337-353, 1996.
39. Fujii, D.E.M.; Ahmed, I.; Jokumsen, M.; and Compton, J.M. The effects of clozapine on cognitive functioning in treatment-resistant schizophrenic patients. Journal of Neuropsychiatry, 22:240-245, 1997.
40. Galletly, C.A.; Clark, R.C.; McFarlane, A.C.; and Weber, D.L. The relationship between changes in symptom ratings, neuropsychological test performance, and quality of life in schizophrenic patients treated with clozapine. Psychiatry Research, 72:161-166, 1997.
41. Gallhofer, B.; Bauer, U.; Lis, S.; Krieger, S.; and Gruppe, H. Cognitive dysfunction in schizophrenia: Comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. European Neuropsychopharmacology, 6 (Suppl. 2):13-20, 1996.
42. Gelenberg, A.J.; Van Putten, T.; Lavori, P.W.; Wojcik, J.D.; Falk, W.E.; Marder, S.; Galvin-Nadeau, M.; Spring, B.; Mohs, R.C.; and Brotman, A.W. Anticholinergic effects on memory: Benztropine versus amantadine. Journal of Clinical Psychopharmacology, 9:180-185, 1989.
43. Ghoneim, M.M., and Mewaldt, S.P. Studies on human memory: The interactions of diazepam, scopolamine, and physostigmine. Psychopharmacology, 52:1-6, 1977.
44. Gilbertson, M.W., and van Kammen, D.P. Recent and remote memory dissociation: Medication effect and hippocampal function in schizophrenia. Biological Psychiatry, 42:585-595, 1997.
45. Goldberg, T.E.; Greenberg, R.D.; Griffin, S.J.; Gold, J.M.; Kleinman, J.E.; Pickar, D.; Schulz, S.C.; and Weinberger, D.R. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. British Journal of Psychiatry, 162:43-48, 1993.
46. Goldman-Rakic, P.S., and Selemon, L.D. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophrenia Bulletin, 23:437-458, 1997.
47. Green, M.F. What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry, 153:321-330, 1996.
48. Green, M.F.; Marshall, B.D.; Wirshing, W.C.; Ames, D.; Marder, S.R.; McGurk, S.; Kern, R.S.; and Mintz, J. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? American Journal of Psychiatry, 154:799-804, 1997.
49. Hagger, C.; Buckley, P.; Kenny, J.T.; Friedman, L.; Ubogy, D.; and Meltzer, H.Y. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biological Psychiatry, 34:702-712, 1993.
50. Harvey, J.A. Serotonergic regulation of associative learning. Behavior Brain Research, 73:47-50, 1996.
51. Harvey, J.A.; Gormezano, I.; and Cool-Haser, V.A. Effects of scopolamine and methylscopolamine on classical conditioning of the rabbit nictitating membrane response. Journal of Pharmacology and Experimental Therapeutics, 225:42-49, 1983.
52. Harvey, P.D., and Keefe, R.S.E. Standards for the assessment of cognitive change in schizophrenia treatment studies. Submitted.
53. Harvey, P.D., and Pedley, M. Auditory and visual distractibility in schizophrenics: Clinical and medication status correlates. Psychiatry Research, 2:295-300, 1989.
54. Hoff, A.L.; Faustman, W.O.; Wieneke, M.; Espinoza, S.; Costa, M.; Wolkowitz, O.; and Csernansky, J.G. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology, 15:361-369, 1996.
55. Holttum, J.R., and Gershon, S. The cholinergic model of dementia, Alzheimer type: Progression from the unitary transmitter concept. Dementia, 3:174-185, 1992.
56. Jackson, W.J., and Buccafusco, J.J. Clonidine enhanced delayed matching-to-sample performance by young and aged monkeys. Pharmacology, Biochemistry and Behavior, 39:79-84, 1991.
57. Kant, G.J.; Meininger, G.R.; Maughan, K.R.; Wright, W.L.; Robinson, T.N. III; and Neely, T.M. Effects of the serotonin receptor agonists 8-OH-DPAT and TFMPP on learning as assessed using a novel water maze. Pharmacology, Biochemistry and Behavior, 53:385-390, 1996.
58. Keefe, R.S.E.; Mohs, R.C.; Losonczy, M.F.; Davidson, M.; Silverman, J.M.; Kendler, K.S.; Nora, R.; Horvath, T.B.; and Davis, K.L. Characteristics of very poor outcome schizophrenia. American Journal of Psychiatry, 144:889-895, 1987.
59. Kern, R.S.; Green, M.F.; Marshall, B.D. Jr.; Wirshing, W.C.; Wirshing, D.; McGurk, S.; Marder, S.R.; and Mintz, J. Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenic patients. Biological Psychiatry. In press.
60. Lee, M.A.; Thompson, P.A.; and Meltzer, H.Y. Effects of clozapine on cognitive function in schizophrenia. Journal of Clinical Psychiatry, 55(Suppl. B):82-87, 1994.
61. Levin, E.D. Psychopharmacological effects in the radial-arm maze. Neuroscience Biobehavioral Reviews, 12:169-175, 1988a.
62. Levin, E.D. Scopolamine interactions with D1 and D2 antagonists on radial-arm maze performance in rats. Behavioral and Neural Biology, 50:240-245, 1988b.
63. Levin, E.D.; Galen, D.; and Ellison, G.D. Chronic haloperidol effects on radial arm maze performance and oral movements in rats. Pharmacology, Biochemistry and Behavior, 26:1-6, 1987.
64. Levin, E.D., and Gunne, L.M. Chronic neuroleptic effects on spatial reversal learning in monkeys. Psychopharmacology, 97:496-500, 1989.
65. Levin, E.D., and Rose, J.E. Interactive effects of D1 and D2 agonists with scopolamine on radial-arm maze performance. Pharmacology, Biochemistry and Behavior, 38:243-246, 1991.
66. 2 adrenergic antagonist yohimbine into the dorsolateral prefrontal cortex in young adult monkeys. Behavioral and Neural Biology, 62:134-139, 1994.
67. Lieberman, J.A.; Safferman, A.Z.; Pollack, S.; Szymanski, S.; Johns, C.; Howard, A.; Kronig, M.; Bookstein, P.; and Kane, J.M. Clinical effects of clozapine in chronic schizophrenia: Response to treatment and predictors of outcome. American Journal of Psychiatry, 151:1744-1752, 1994.
68. Luciana, M.; DePue, R.A.; Arbisis, P.; and Leon, A. Facilitation of working memory in humans by a D2 dopamine receptor agonist. Journal of Cognitive Neuroscience, 4:58-68, 1992.
69. Marder, S.R.; Asarnow, R.F.; and van Putten, T. Information processing and neuroleptic response in acute and stabilized schizophrenic patients. Psychiatry Research, 13:41-49, 1984.
70. McEvoy, J.P.; McCue, M.; Spring, C.M.; Lavori, P.W.; and Farr, R.M. Effects of amantadine and trihexyphenidyl on memory in elderly normal volunteers. American Journal of Psychiatry, 144:573-577, 1987.
71. McGurk, S.R.; Green, M.F.; Wirshing, W.C.; Ames, D.; Marshall, B.D. Jr.; Marder, A.R.; and Mintz, J. The effects of risperidone vs. haloperidol on cognitive functioning in treatment-resistant schizophrenia: The Trail Making Test. CNS Spectrums, 2:60-64, 1997.
72. McGurk, S.R.; Levin, E.D.; and Butcher, L.L. Cholinergic-dopaminergic interactions in radial-arm maze performance. Behavioral and Neural Biology, 49:234-239, 1988.
73. Medalia, A.; Gold, J.M.; and Merriam, A. The effects of neuroleptics on neuropsychological test results of schizophrenics. Archives of Clinical Neuropsychology, 3:249-271, 1988.
74. Meltzer, H.Y., and McGurk, S.R. The effect of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin, 25(2):233-255, 1999.
75. Meneses, A., and Hong, E. A pharmacological analysis of serotonergic receptors: Effects of their activation or blockade in learning. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 21:273-296, 1997.
76. Mewaldt, S.P., and Ghoneim, M.M. The effect and interactions of scopolamine, physostigmine, and methamphetamine on human memory. Pharmacology, Biochemistry and Behavior, 10:1205-1210, 1979.
77. Meyer-Lindenberg, A.; Gruppe, H.; Bauer, U.; Lis, S.; Krieger, S.; and Gallhofer, B. Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: Results from a double-blind study. Pharmacopsychiatry, 30(2):35-42, 1997.
78. Peretti, C.S.; Danion, J.M.; Kauffmann-Muller, F.; Grange, D.; Patat, A.; and Rosenzweig, P. Effects of haloperidol and amisulpride on motor and cognitive skill learning in healthy volunteers. Psychopharmacology, 131:329-338, 1997.
79. Perlick, D.; Stastny, P.; Katz, I.; Mayer, M.; and Mattis, S. Memory deficits and anticholinergic levels in chronic schizophrenia. American Journal of Psychiatry, 143:230-232, 1986.
80. Riedel, G.; Wetzel, W.; and Reymann, K.G. Comparing the role of metabotropic glutamate receptors in long-term potentiation and in learning and memory. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 20:761-789, 1996.
81. Riekkinen, M.; Riekkinen, P.; Sirvio, J.; and Riekkinen, P. Jr. Effects of combined methysergide and mecamylamine/scopolamine treatment on spatial navigation. Brain Research, 585:322-326, 1992.
82. Rosenheck, R.; Cramer, J.; Xu, W.; Thomas, J.; Henderson, W.; Frisman, L.; Fye, C.; and Charney, D. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. New England Journal of Medicine, 337:809-815, 1997.
83. Rosenthal, R. Combining results of independent studies. Psychological Bulletin, 85(1):185-193, 1978.
84. Rosenthal, R., and Rubin, D.B. Meta-analytic procedures for combining studies with multiple effect sizes. Psychological Bulletin, 99(3):400-406, 1986.
85. Rosic, N.; Bokonjic, D.; and Overstreet, D.H. Task-dependent development of tolerance to scopolamine. Pharmacology, Biochemistry and Behavior, 13(2):183-186, 1980.
86. Rossi, A.; Mancini, F.; Stratta, P.; Mattei, P.; Gismondi, R.; Pozzi, F.; and Casacchia, M. Risperidone, negative symptoms, and cognitive deficit in schizophrenia: An open study. Acta Psychiatrica Scandinavica, 95:40-43, 1997.
87. Sakurai, Y., and Wenk, G.L. The interaction of acetylcholinergic and serotonergic neural systems on performance in a continuous non-matching to sample task. Brain Research, 519:118-121, 1990.
88. Sawaguchi, T., and Goldman-Rakic, P.S. D1 dopamine receptors in prefrontal cortex: Involvement in working memory. Science, 251:947-950, 1991.
89. Sawaguchi, T., and Goldman-Rakic, P.S. The role of D1-dopamine receptor in working memory: Local actions of dopamine antagonists into the prefrontal cortex of rhesus monkey performing an occulomotor delayed-response task. Journal of Neurophysiology, 71:515-528, 1994.
90. Serper, M.R., and Chou, J.C.Y. Novel neuroleptics improve attentional functioning in schizophrenic patients: Ziprasidone and aripiprazole. CNS Spectrums, 2:56-59, 1997.
91. Serper, M.R.; Davidson, M.; and Harvey, P.D. Attentional predictors of clinical change during neuroleptic treatment for schizophrenia. Schizophrenia Research, 13:65-71, 1994.
92. Silver, H., and Geraisy, N. Effects of biperiden and amantadine on memory in medicated chronic schizophrenic patients: A double blind cross-over study. British Journal of Psychiatry, 166:241-243, 1995.
93. Sirvio, J.; Riekkinen, P.; Pekka, J.; and Riekkinen, P.J. Experimental studies on the role of serotonin in cognition. Progress in Neurobiology, 43:363-379, 1994.
94. Sorokin, J.E.; Giordani, B.; Mohs, R.C.; Losonczy, M.F.; Davidson, M.; Siever, L.J.; Ryan, T.A.; and Davis, K.L. Memory impairment in schizophrenic patients with tardive dyskinesia. Biological Psychiatry, 23:129-135, 1988.
95. Spohn, H.E.; Coyne, L.; and Spray, J. The effect of neuroleptics and tardive dyskinesia on smooth-pursuit eye movement in chronic schizophrenics. Archives of General Psychiatry, 45:833-840, 1988.
96. Stip, E., and Lussier, I. The effect of risperidone on cognition in patients with schizophrenia. Canadian Journal of Psychiatry, 41(Suppl. 2):35-40, 1996.
97. Strauss, M.E.; Reynolds, K.S.; Jayaram, G.; and Tune, L.E. Effects of anticholinergic medication on memory in schizophrenia. Schizophrenia Research, 3:127-129, 1990.
98. Sweeney, J.A.; Keilp, J.G.; Haas, G.L.; Hill, J.; and Weiden, P.J. Relationships between medication treatments and neuropsychological test performance in schizophrenia. Psychiatry Research, 37:297-308, 1991.
99. Tamlyn, D.; McKenna, P.J.; Mortimer, A.M.; Lund, C.E.; Hammond, S.; and Baddeley, A.D. Memory impairment in schizophrenia: Its extent, affiliations, and neuropsychological character. Psychological Medicine, 22:101-115, 1992.
100. Tune, L.E.; Strauss, M.E.; Lew, M.F.; Breitlinger, E.; and Cole, J.T. Serum levels of anticholinergic drug and impaired recent memory in chronic schizophrenic patients. American Journal of Psychiatry, 139:1460-1462, 1982.
101. Van Tol, H.H.; Bunzow, J.R.; Guan, H.C.; Sunahara, R.K.; Seeman, P.; Niznik, H.B.; and Civelli, O. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature, 350(6319):610-614, 1991.
102. Vitiello, B.; Martin, A.; Hill, J.; Mack, C.; Molchan, S.; Martinez, R.; Murphy, D.L.; and Sunderland, T. Cognitive and behavioral effects of cholinergic, dopaminergic, and serotonergic blockade in humans. Neuropsychopharmacology, 16:15-24, 1997.
103. Walker, E., and Green, M.F. Motor proficiency and attention-task performance by schizophrenic patients. Journal of Abnormal Psychology, 91:261-268, 1982.
104. Warburton, E.C.; Harrison, A.A.; Robbins, T.W.; and Everitt, B.J. Contrasting effects of systemic and intracerebral infusions of the 5-HT1A receptor agonist 8-OH-DPAT on spatial short-term working memory in rats. Behavioral Brain Research, 84:247-258, 1997.
105. Williams, G.V., and Goldman-Rakic, P.S. Modulation of memory fields by dopamine D1 receptors in prefronal cortex. Nature, 376:572-575, 1995.
106. Wilson, W.H. Time required for initial improvement during clozapine treatment of refractory schizophrenia. American Journal of Psychiatry, 153:951-952, 1996.
107. Wishaw, I.Q. Dissociating performance and learning deficits on spatial navigation tasks in rats subjected to cholinergic muscarinic blockade. Brain Research Bulletin, 23:347-358, 1989.
108. Zahn, T.P.; Pickar, D.; and Haier, R.J. Effects of clozapine, flufenazine, and placebo on reaction time measures of attention and sensory dominance in schizophrenia. Schizophrenia Research, 13:133-144, 1994.